ADIL

Business Context and Reporting Period

Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2025
Event Date: June 18, 2025 (Closing Date)
Context: The Company consummated a best efforts public offering of common stock, pre-funded warrants, and common warrants to raise capital for working capital and general corporate purposes.

Key Financial Metrics and Capital Structure

Offering Proceeds: Approximately $3.6 million in aggregate gross proceeds (before fees and expenses).
Securities Issued:

• Common Stock: 5,341,200 shares.
• Pre-Funded Warrants: 5,758,800 warrants (exercisable at $0.001/share).
• Series D Warrants: 11,100,000 warrants (exercisable at $0.35/share; 5-year term).
• Series E Warrants: 8,325,000 warrants (exercisable at $0.35/share; 18-month term).

Offering Price:

• Combined price for Share + Warrants: $0.3251.
• Combined price for Pre-Funded Warrant + Warrants: $0.3241.

Outstanding Shares: 15,775,895 shares of Common Stock (post-offering, excluding warrant exercises).
Transaction Costs:

• Placement Agent Fee: 7.0% of gross proceeds (with a 3.5% credit for tail fee investors).
• Management Fee: 1.0% of gross proceeds.
• Expense Reimbursement: Up to $75,000 for legal and other expenses.

Debt and Liquidity: The filing text does not provide specific values for total debt, cash on hand, or liquidity ratios prior to or after the offering.

Material Changes and Agreements

Warrant Amendments:

• Amended Series B-1 (2,482,270 shares) and Series C-1 (4,025,000 shares) warrants.
• Exercise Price Reduction: Reduced to $0.35 per share.
• Term Extension: Series B-1 extended to June 17, 2030; Series C-1 extended to December 17, 2026.

Lock-Up Provisions:

• Company and executive officers/directors are restricted from issuing or selling securities for 30 days post-closing.
• Company is restricted from issuing common stock or equivalents for 30 days, and from "at-the-market" offerings for 60 days post-closing (with specific exceptions for an existing ATM facility and an Equity Purchase Agreement with Alumni Capital LP).

Stockholder Approval Requirement: The Company must hold a stockholder meeting within 120 days of the Closing Date to obtain approval for the issuance of shares underlying the Common Warrants. If not obtained, meetings must be called every 90 days thereafter.

Outlook, Risks, and Contingencies

Use of Proceeds: Primarily for working capital and general corporate purposes.
Warrant Exercise Restrictions: Holders are generally limited to owning 4.99% (or 9.99% with notice) of outstanding shares immediately after exercise.
Fundamental Transaction Rights: In the event of a fundamental transaction, warrant holders may have the right to require the Company to repurchase warrants at the Black Scholes Value, subject to specific conditions regarding Company control and board approval.
Registration Status: Securities were issued pursuant to a Registration Statement on Form S-1 effective June 16, 2025.

Investor Verification Checklist

• Net Proceeds: Verify the actual net cash received after deducting the 8% total placement fees and the $75,000 expense cap.
• Dilution Impact: Assess the potential dilution from the 19,425,000 new warrants (Series D and E) and 5,758,800 pre-funded warrants if exercised.
• Stockholder Approval: Monitor the Company's ability to secure stockholder approval for the warrant shares within the required 120-day window.
• Warrant Economics: Confirm the impact of the reduced $0.35 exercise price on existing Series B-1 and C-1 warrant holders versus the new offering price.
• Liquidity Position: Review the most recent 10-Q or 10-K to determine the Company's cash runway given the $3.6 million gross raise.